Kelley M. Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kelley M. Anderson has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Nawar Shara
Center of Biostatistics, Informatics and Data Science at MedStar Health Research Institute (MHRI), USA and Health Data Science at Georgetown University (GU), USA
8 shared publications - Anirudh Rao
Department of Medicine, MedStar Washington Hospital Center, Washington, DC; Georgetown University School of Medicine, Washington, DC
4 shared publications - Bethany Talmadge
Invaryant Inc, Roswell, GA, United States
4 shared publications Hunter Groninger
Department of Medicine, MedStar Washington Hospital Center, Washington, District of Columbia, USA
4 shared publications- Margrét Vilborg Bjarnadóttir
Robert H. Smith School of Business, University of Maryland, College Park, Maryland 20742
4 shared publications - Maryam Ahmad
MedStar Health Research Institute, Hyattesville, MD, United States
4 shared publications
Latest Publications
- 21 November 2025
- Published by Elsevier in Heart & Lung
- Vol. 76, 174-189
Cardiac cachexia: A scientific statement from the American Association of Heart Failure Nurses (AAHFN)
- 21 November 2025
- Published by Elsevier in Heart & Lung
- Vol. 76, 174-189
Cardiac cachexia: A scientific statement from the American Association of Heart Failure Nurses (AAHFN)
- 10 October 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (10) , 1377-1379
Outcomes of Heart Failure Patients on Palliative Inotrope Therapy in the Hospice Setting: A Single Center Retrospective Cohort Study
Background: Chronic intravenous inotropic support (CIIS) is recommended as palliative therapy for end-stage heart failure (HF) but is underutilized in hospice settings. Objectives: This study evaluates outcomes for patients on CIIS receiving hospice care. Design: Retrospective cohort study using electronic health records of patients on CIIS admitted to hospice. Setting/Subjects: Twenty-one patients admitted to a mid-Atlantic hospice between 2018 and 2022. Measurements: Data collected included demographics, inotropic therapy details, hospice length of stay (LOS), hospitalizations, and medication usage. Results: The mean age was 72.9 years; 67% were on milrinone. Patients had a mean hospice LOS of 49.6 days, with 66% experiencing no hospitalizations. Only 24% of patients required high-dose opioids. 24% of patients were discharged alive from hospice, and 52% died at home. Conclusion: Caring for patients on CIIS in hospice appears feasible and may portend some benefits to patients. Further research is warranted to confirm these findings in a prospective observational cohort.
- 10 October 2025
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 28 (10) , 1377-1379
Outcomes of Heart Failure Patients on Palliative Inotrope Therapy in the Hospice Setting: A Single Center Retrospective Cohort Study
Background: Chronic intravenous inotropic support (CIIS) is recommended as palliative therapy for end-stage heart failure (HF) but is underutilized in hospice settings. Objectives: This study evaluates outcomes for patients on CIIS receiving hospice care. Design: Retrospective cohort study using electronic health records of patients on CIIS admitted to hospice. Setting/Subjects: Twenty-one patients admitted to a mid-Atlantic hospice between 2018 and 2022. Measurements: Data collected included demographics, inotropic therapy details, hospice length of stay (LOS), hospitalizations, and medication usage. Results: The mean age was 72.9 years; 67% were on milrinone. Patients had a mean hospice LOS of 49.6 days, with 66% experiencing no hospitalizations. Only 24% of patients required high-dose opioids. 24% of patients were discharged alive from hospice, and 52% died at home. Conclusion: Caring for patients on CIIS in hospice appears feasible and may portend some benefits to patients. Further research is warranted to confirm these findings in a prospective observational cohort.
- 16 July 2025
- Published by Elsevier in Nursing Outlook
- Vol. 73 (5) , 102491
Nursing disciplinary knowledge: Honoring the past and envisioning a future of PhD nursing education to advance health equity
- 16 July 2025
- Published by Elsevier in Nursing Outlook
- Vol. 73 (5) , 102491
Nursing disciplinary knowledge: Honoring the past and envisioning a future of PhD nursing education to advance health equity
- Open Access
- 13 January 2025
- Published by Wiley in JCSM Communications
- Vol. 8 (1)
Cardiac Cachexia and the Associations to the Microbiome: State‐of‐the‐Science Review
Background: Cardiac cachexia is a late manifestation of advanced heart failure, with a 5%–15% prevalence. A diagnosis of cardiac cachexia is not simply another complication of heart failure; clinical consequences of cachexia are impaired physical function, fatigue, poor quality of life and independently associated with heart failure severity, adverse cardiovascular and non‐cardiovascular outcomes, longer length of hospital stays and increased mortality. Although it is well established that cardiac cachexia is associated with poor outcomes, there remains a lack of evidence describing the underlying mechanisms that has resulted in limited impactful treatment modalities. Contemporary explorations describe the association of the gut microbiome related to many health conditions, including heart failure. Preclinical and clinical studies are defining the role of the microbiome and the associations to heart failure and comorbidities including cardiac cachexia.Methods: In this review, we summarize the relevant literature to (1) describe the diagnosis and evaluation of cachexia in individuals with heart failure; (2) provide an overview of the heart–gut axis; (3) report on the gut microbiome as a mediator of cardiac cachexia with a focus on inflammation and protein loss; (4) detail the clinical characterizations and manifestations of cardiac cachexia; (5) review current treatment modalities for cardiac cachexia and their limitations; and (6) provide recommendations for future lines of inquiry for heart failure–related cachexia and the microbiome.Results: Current clinical and animal studies are developing the science to expand our understanding of the association of the microbiome to the clinical expression of cardiovascular conditions, including heart failure and related conditions, including cachexia. Elucidating mechanisms of cachexia will provide the foundational evidence to improve treatment approaches. Available treatments are limited and do not meaningfully impact the illness experience of patients with heart failure and cachexia. Improving our understanding of the innovative concept of the heart–gut axis has the potential for significant clinical advances in developing novel diagnostic and therapeutic approaches for heart failure and for evaluating a common pathway for cachexia.Conclusions: In this review, we discuss the characteristics, evaluation, impact on prognosis and therapeutic interventions of cachexia and the current state of the science related to the role of the microbiome in cardiac cachexia. Although the current evidence is limited, there are numerous opportunities for collaborative efforts among translational researchers to understand the underlying mechanisms of cardiac cachexia and the relationship to the gut microbiome and to develop innovative therapeutic treatment interventions for patients with advanced heart failure.
- 13 January 2025
- Published by Wiley in JCSM Communications
- Vol. 8 (1)
Open AccessCardiac Cachexia and the Associations to the Microbiome: State‐of‐the‐Science Review
Background: Cardiac cachexia is a late manifestation of advanced heart failure, with a 5%–15% prevalence. A diagnosis of cardiac cachexia is not simply another complication of heart failure; clinical consequences of cachexia are impaired physical function, fatigue, poor quality of life and independently associated with heart failure severity, adverse cardiovascular and non‐cardiovascular outcomes, longer length of hospital stays and increased mortality. Although it is well established that cardiac cachexia is associated with poor outcomes, there remains a lack of evidence describing the underlying mechanisms that has resulted in limited impactful treatment modalities. Contemporary explorations describe the association of the gut microbiome related to many health conditions, including heart failure. Preclinical and clinical studies are defining the role of the microbiome and the associations to heart failure and comorbidities including cardiac cachexia.Methods: In this review, we summarize the relevant literature to (1) describe the diagnosis and evaluation of cachexia in individuals with heart failure; (2) provide an overview of the heart–gut axis; (3) report on the gut microbiome as a mediator of cardiac cachexia with a focus on inflammation and protein loss; (4) detail the clinical characterizations and manifestations of cardiac cachexia; (5) review current treatment modalities for cardiac cachexia and their limitations; and (6) provide recommendations for future lines of inquiry for heart failure–related cachexia and the microbiome.Results: Current clinical and animal studies are developing the science to expand our understanding of the association of the microbiome to the clinical expression of cardiovascular conditions, including heart failure and related conditions, including cachexia. Elucidating mechanisms of cachexia will provide the foundational evidence to improve treatment approaches. Available treatments are limited and do not meaningfully impact the illness experience of patients with heart failure and cachexia. Improving our understanding of the innovative concept of the heart–gut axis has the potential for significant clinical advances in developing novel diagnostic and therapeutic approaches for heart failure and for evaluating a common pathway for cachexia.Conclusions: In this review, we discuss the characteristics, evaluation, impact on prognosis and therapeutic interventions of cachexia and the current state of the science related to the role of the microbiome in cardiac cachexia. Although the current evidence is limited, there are numerous opportunities for collaborative efforts among translational researchers to understand the underlying mechanisms of cardiac cachexia and the relationship to the gut microbiome and to develop innovative therapeutic treatment interventions for patients with advanced heart failure.
- Open Access
- 3 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e54991
Health Care Usage During the COVID-19 Pandemic and the Adoption of Telemedicine: Retrospective Study of Chronic Disease Cohorts
Background: The COVID-19 pandemic accelerated telehealth adoption across disease cohorts of patients. For many patients, routine medical care was no longer an option, and others chose not to visit medical offices in order to minimize COVID-19 exposure. In this study, we take a comprehensive multidisease approach in studying the impact of the COVID-19 pandemic on health care usage and the adoption of telemedicine through the first 12 months of the COVID-19 pandemic. Objective: We studied the impact of the COVID-19 pandemic on in-person health care usage and telehealth adoption across chronic diseases to understand differences in telehealth adoption across disease cohorts and patient demographics (such as the Social Vulnerability Index [SVI]). Methods: We conducted a retrospective cohort study of 6 different disease cohorts (anxiety: n=67,578; depression: n=45,570; diabetes: n=81,885; kidney failure: n=29,284; heart failure: n=21,152; and cancer: n=35,460). We used summary statistics to characterize changes in usage and regression analysis to study how patient characteristics relate to in-person health care and telehealth adoption and usage during the first 12 months of the pandemic. Results: We observed a reduction in in-person health care usage across disease cohorts (ranging from 10% to 24%). For most diseases we study, telehealth appointments offset the reduction in in-person visits. Furthermore, for anxiety and depression, the increase in telehealth usage exceeds the reduction in in-person visits (by up to 5%). We observed that younger patients and men have higher telehealth usage after accounting for other covariates. Patients from higher SVI areas are less likely to use telehealth; however, if they do, they have a higher number of telehealth visits, after accounting for other covariates. Conclusions: The COVID-19 pandemic affected health care usage across diseases, and the role of telehealth in replacing in-person visits varies by disease cohort. Understanding these differences can inform current practices and provides opportunities to further guide modalities of in-person and telehealth visits. Critically, further study is needed to understand barriers to telehealth service usage for patients in higher SVI areas. A better understanding of the role of social determinants of health may lead to more support for patients and help individual health care providers improve access to care for patients with chronic conditions.
- 3 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e54991
Open AccessHealth Care Usage During the COVID-19 Pandemic and the Adoption of Telemedicine: Retrospective Study of Chronic Disease Cohorts
Background: The COVID-19 pandemic accelerated telehealth adoption across disease cohorts of patients. For many patients, routine medical care was no longer an option, and others chose not to visit medical offices in order to minimize COVID-19 exposure. In this study, we take a comprehensive multidisease approach in studying the impact of the COVID-19 pandemic on health care usage and the adoption of telemedicine through the first 12 months of the COVID-19 pandemic. Objective: We studied the impact of the COVID-19 pandemic on in-person health care usage and telehealth adoption across chronic diseases to understand differences in telehealth adoption across disease cohorts and patient demographics (such as the Social Vulnerability Index [SVI]). Methods: We conducted a retrospective cohort study of 6 different disease cohorts (anxiety: n=67,578; depression: n=45,570; diabetes: n=81,885; kidney failure: n=29,284; heart failure: n=21,152; and cancer: n=35,460). We used summary statistics to characterize changes in usage and regression analysis to study how patient characteristics relate to in-person health care and telehealth adoption and usage during the first 12 months of the pandemic. Results: We observed a reduction in in-person health care usage across disease cohorts (ranging from 10% to 24%). For most diseases we study, telehealth appointments offset the reduction in in-person visits. Furthermore, for anxiety and depression, the increase in telehealth usage exceeds the reduction in in-person visits (by up to 5%). We observed that younger patients and men have higher telehealth usage after accounting for other covariates. Patients from higher SVI areas are less likely to use telehealth; however, if they do, they have a higher number of telehealth visits, after accounting for other covariates. Conclusions: The COVID-19 pandemic affected health care usage across diseases, and the role of telehealth in replacing in-person visits varies by disease cohort. Understanding these differences can inform current practices and provides opportunities to further guide modalities of in-person and telehealth visits. Critically, further study is needed to understand barriers to telehealth service usage for patients in higher SVI areas. A better understanding of the role of social determinants of health may lead to more support for patients and help individual health care providers improve access to care for patients with chronic conditions.
- 1 August 2024
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 27 (8) , 1026-1032
Disease-State Understanding and Experience of Patients Receiving Continuous Intravenous Inotropic Support as Palliative Therapy: A Multicenter Survey
Background: The use of continuous intravenous inotropic support (CIIS) as palliative therapy in patients with advanced heart failure (HF) has increased over the past decade. CIIS improves New York Heart Association (NYHA) functional class but does not impact survival. Objective: The objective of this study was to examine patients' understanding of the therapeutic intent of CIIS, prognostic awareness, and quality of life with CIIS. Design: We conducted a prospective, cross-sectional, multicenter study of patients with advanced HF receiving CIIS as palliative therapy between 2020 and 2022. Settings/Subjects: An investigator-developed survey instrument was administered to outpatients on CIIS in the United States via telephone. Measurements: Survey data were analyzed using descriptive and inferential statistics. Results: Forty-eight patients, 63% male, 81% African American/Black, with a mean age of 68.9 (standard deviation 12.3) years, participated in this study. The majority of patients responded that they expected CIIS to make them feel better (79%) and increase longevity (75%), but few expected that CIIS would cure their HF (19%). Patients described their overall quality of life on CIIS as not better/worse (19%), somewhat better (46%), and significantly better (35%) and reported high treatment satisfaction (87% were at least somewhat satisfied). Conclusions: In this study, patients report improved quality of life with CIIS as palliative therapy. Patients on CIIS as palliative therapy expected increased survival on CIIS, which is incongruent with current evidence. Further studies on how we can improve care processes so that patients have accurate prognostic and disease-state awareness, and receive goal concordant care, are warranted.
- 1 August 2024
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 27 (8) , 1026-1032
Disease-State Understanding and Experience of Patients Receiving Continuous Intravenous Inotropic Support as Palliative Therapy: A Multicenter Survey
Background: The use of continuous intravenous inotropic support (CIIS) as palliative therapy in patients with advanced heart failure (HF) has increased over the past decade. CIIS improves New York Heart Association (NYHA) functional class but does not impact survival. Objective: The objective of this study was to examine patients' understanding of the therapeutic intent of CIIS, prognostic awareness, and quality of life with CIIS. Design: We conducted a prospective, cross-sectional, multicenter study of patients with advanced HF receiving CIIS as palliative therapy between 2020 and 2022. Settings/Subjects: An investigator-developed survey instrument was administered to outpatients on CIIS in the United States via telephone. Measurements: Survey data were analyzed using descriptive and inferential statistics. Results: Forty-eight patients, 63% male, 81% African American/Black, with a mean age of 68.9 (standard deviation 12.3) years, participated in this study. The majority of patients responded that they expected CIIS to make them feel better (79%) and increase longevity (75%), but few expected that CIIS would cure their HF (19%). Patients described their overall quality of life on CIIS as not better/worse (19%), somewhat better (46%), and significantly better (35%) and reported high treatment satisfaction (87% were at least somewhat satisfied). Conclusions: In this study, patients report improved quality of life with CIIS as palliative therapy. Patients on CIIS as palliative therapy expected increased survival on CIIS, which is incongruent with current evidence. Further studies on how we can improve care processes so that patients have accurate prognostic and disease-state awareness, and receive goal concordant care, are warranted.
- 18 June 2024
- Published by Springer Nature
- p. 507-527
Prevention of Heart Failure
- 3 May 2024
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 65 (6) , 527-536
Prognostic Implications of Delirium After Left Ventricular Assist Device Implantation: A Retrospective Study
- 3 May 2024
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 65 (6) , 527-536
Prognostic Implications of Delirium After Left Ventricular Assist Device Implantation: A Retrospective Study
- Open Access
- 22 April 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8 (1) , e53091
Use of Machine Learning for Early Detection of Maternal Cardiovascular Conditions: Retrospective Study Using Electronic Health Record Data
Background: Cardiovascular conditions (eg, cardiac and coronary conditions, hypertensive disorders of pregnancy, and cardiomyopathies) were the leading cause of maternal mortality between 2017 and 2019. The United States has the highest maternal mortality rate of any high-income nation, disproportionately impacting those who identify as non-Hispanic Black or Hispanic. Novel clinical approaches to the detection and diagnosis of cardiovascular conditions are therefore imperative. Emerging research is demonstrating that machine learning (ML) is a promising tool for detecting patients at increased risk for hypertensive disorders during pregnancy. However, additional studies are required to determine how integrating ML and big data, such as electronic health records (EHRs), can improve the identification of obstetric patients at higher risk of cardiovascular conditions. Objective: This study aimed to evaluate the capability and timing of a proprietary ML algorithm, Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology (HOPE-CAT), to detect maternal-related cardiovascular conditions and outcomes. Methods: Retrospective data from the EHRs of a large health care system were investigated by HOPE-CAT in a virtual server environment. Deidentification of EHR data and standardization enabled HOPE-CAT to analyze data without pre-existing biases. The ML algorithm assessed risk factors selected by clinical experts in cardio-obstetrics, and the algorithm was iteratively trained using relevant literature and current standards of risk identification. After refinement of the algorithm’s learned risk factors, risk profiles were generated for every patient including a designation of standard versus high risk. The profiles were individually paired with clinical outcomes pertaining to cardiovascular pregnancy conditions and complications, wherein a delta was calculated between the date of the risk profile and the actual diagnosis or intervention in the EHR. Results: In total, 604 pregnancies resulting in birth had records or diagnoses that could be compared against the risk profile; the majority of patients identified as Black (n=482, 79.8%) and aged between 21 and 34 years (n=509, 84.4%). Preeclampsia (n=547, 90.6%) was the most common condition, followed by thromboembolism (n=16, 2.7%) and acute kidney disease or failure (n=13, 2.2%). The average delta was 56.8 (SD 69.7) days between the identification of risk factors by HOPE-CAT and the first date of diagnosis or intervention of a related condition reported in the EHR. HOPE-CAT showed the strongest performance in early risk detection of myocardial infarction at a delta of 65.7 (SD 81.4) days. Conclusions: This study provides additional evidence to support ML in obstetrical patients to enhance the early detection of cardiovascular conditions during pregnancy. ML can synthesize multiday patient presentations to enhance provider decision-making and potentially reduce maternal health disparities.
- 22 April 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8 (1) , e53091
Open AccessUse of Machine Learning for Early Detection of Maternal Cardiovascular Conditions: Retrospective Study Using Electronic Health Record Data
Background: Cardiovascular conditions (eg, cardiac and coronary conditions, hypertensive disorders of pregnancy, and cardiomyopathies) were the leading cause of maternal mortality between 2017 and 2019. The United States has the highest maternal mortality rate of any high-income nation, disproportionately impacting those who identify as non-Hispanic Black or Hispanic. Novel clinical approaches to the detection and diagnosis of cardiovascular conditions are therefore imperative. Emerging research is demonstrating that machine learning (ML) is a promising tool for detecting patients at increased risk for hypertensive disorders during pregnancy. However, additional studies are required to determine how integrating ML and big data, such as electronic health records (EHRs), can improve the identification of obstetric patients at higher risk of cardiovascular conditions. Objective: This study aimed to evaluate the capability and timing of a proprietary ML algorithm, Healthy Outcomes for all Pregnancy Experiences-Cardiovascular-Risk Assessment Technology (HOPE-CAT), to detect maternal-related cardiovascular conditions and outcomes. Methods: Retrospective data from the EHRs of a large health care system were investigated by HOPE-CAT in a virtual server environment. Deidentification of EHR data and standardization enabled HOPE-CAT to analyze data without pre-existing biases. The ML algorithm assessed risk factors selected by clinical experts in cardio-obstetrics, and the algorithm was iteratively trained using relevant literature and current standards of risk identification. After refinement of the algorithm’s learned risk factors, risk profiles were generated for every patient including a designation of standard versus high risk. The profiles were individually paired with clinical outcomes pertaining to cardiovascular pregnancy conditions and complications, wherein a delta was calculated between the date of the risk profile and the actual diagnosis or intervention in the EHR. Results: In total, 604 pregnancies resulting in birth had records or diagnoses that could be compared against the risk profile; the majority of patients identified as Black (n=482, 79.8%) and aged between 21 and 34 years (n=509, 84.4%). Preeclampsia (n=547, 90.6%) was the most common condition, followed by thromboembolism (n=16, 2.7%) and acute kidney disease or failure (n=13, 2.2%). The average delta was 56.8 (SD 69.7) days between the identification of risk factors by HOPE-CAT and the first date of diagnosis or intervention of a related condition reported in the EHR. HOPE-CAT showed the strongest performance in early risk detection of myocardial infarction at a delta of 65.7 (SD 81.4) days. Conclusions: This study provides additional evidence to support ML in obstetrical patients to enhance the early detection of cardiovascular conditions during pregnancy. ML can synthesize multiday patient presentations to enhance provider decision-making and potentially reduce maternal health disparities.
- Open Access
- 29 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Health Care Usage During the COVID-19 Pandemic and the Adoption of Telemedicine: Retrospective Study of Chronic Disease Cohorts (Preprint)
BACKGROUND The COVID-19 pandemic accelerated telehealth adoption across disease cohorts of patients. For many patients, routine medical care was no longer an option, and others chose not to visit medical offices in order to minimize COVID-19 exposure. In this study, we take a comprehensive multidisease approach in studying the impact of the COVID-19 pandemic on health care usage and the adoption of telemedicine through the first 12 months of the COVID-19 pandemic. OBJECTIVE We studied the impact of the COVID-19 pandemic on in-person health care usage and telehealth adoption across chronic diseases to understand differences in telehealth adoption across disease cohorts and patient demographics (such as the Social Vulnerability Index [SVI]). METHODS We conducted a retrospective cohort study of 6 different disease cohorts (anxiety: n=67,578; depression: n=45,570; diabetes: n=81,885; kidney failure: n=29,284; heart failure: n=21,152; and cancer: n=35,460). We used summary statistics to characterize changes in usage and regression analysis to study how patient characteristics relate to in-person health care and telehealth adoption and usage during the first 12 months of the pandemic. RESULTS We observed a reduction in in-person health care usage across disease cohorts (ranging from 10% to 24%). For most diseases we study, telehealth appointments offset the reduction in in-person visits. Furthermore, for anxiety and depression, the increase in telehealth usage exceeds the reduction in in-person visits (by up to 5%). We observed that younger patients and men have higher telehealth usage after accounting for other covariates. Patients from higher SVI areas are less likely to use telehealth; however, if they do, they have a higher number of telehealth visits, after accounting for other covariates. CONCLUSIONS The COVID-19 pandemic affected health care usage across diseases, and the role of telehealth in replacing in-person visits varies by disease cohort. Understanding these differences can inform current practices and provides opportunities to further guide modalities of in-person and telehealth visits. Critically, further study is needed to understand barriers to telehealth service usage for patients in higher SVI areas. A better understanding of the role of social determinants of health may lead to more support for patients and help individual health care providers improve access to care for patients with chronic conditions. CLINICALTRIAL
- 29 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessHealth Care Usage During the COVID-19 Pandemic and the Adoption of Telemedicine: Retrospective Study of Chronic Disease Cohorts (Preprint)
BACKGROUND The COVID-19 pandemic accelerated telehealth adoption across disease cohorts of patients. For many patients, routine medical care was no longer an option, and others chose not to visit medical offices in order to minimize COVID-19 exposure. In this study, we take a comprehensive multidisease approach in studying the impact of the COVID-19 pandemic on health care usage and the adoption of telemedicine through the first 12 months of the COVID-19 pandemic. OBJECTIVE We studied the impact of the COVID-19 pandemic on in-person health care usage and telehealth adoption across chronic diseases to understand differences in telehealth adoption across disease cohorts and patient demographics (such as the Social Vulnerability Index [SVI]). METHODS We conducted a retrospective cohort study of 6 different disease cohorts (anxiety: n=67,578; depression: n=45,570; diabetes: n=81,885; kidney failure: n=29,284; heart failure: n=21,152; and cancer: n=35,460). We used summary statistics to characterize changes in usage and regression analysis to study how patient characteristics relate to in-person health care and telehealth adoption and usage during the first 12 months of the pandemic. RESULTS We observed a reduction in in-person health care usage across disease cohorts (ranging from 10% to 24%). For most diseases we study, telehealth appointments offset the reduction in in-person visits. Furthermore, for anxiety and depression, the increase in telehealth usage exceeds the reduction in in-person visits (by up to 5%). We observed that younger patients and men have higher telehealth usage after accounting for other covariates. Patients from higher SVI areas are less likely to use telehealth; however, if they do, they have a higher number of telehealth visits, after accounting for other covariates. CONCLUSIONS The COVID-19 pandemic affected health care usage across diseases, and the role of telehealth in replacing in-person visits varies by disease cohort. Understanding these differences can inform current practices and provides opportunities to further guide modalities of in-person and telehealth visits. Critically, further study is needed to understand barriers to telehealth service usage for patients in higher SVI areas. A better understanding of the role of social determinants of health may lead to more support for patients and help individual health care providers improve access to care for patients with chronic conditions. CLINICALTRIAL